A groundbreaking clinical trial utilizing technology developed previously by Jeffrey R. Millman, PhD has reported promising new findings in the treatment of type 1 diabetes (T1D). The study, conducted by Vertex Pharmaceuticals, evaluated a stem cell-derived islet (SC-islet) replacement therapy known as Zimislecel. In this Phase 1/2 trial, researchers implanted SC-islets into patients with T1D to replace the non-functioning pancreatic islets responsible for insulin production.
Millman’s technology succeeds in new stem cell therapy trial, offering hope for type 1 diabetes
View Content